Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03065517 · ClinicalTrials.gov registry record · NA
VillageWhere: Innovative Mobile Technology for Youth With Conduct Disorder and Their Parents
A NA study, sponsored by Evidence-Based Practice Institute, Seattle, WA.
- Completed
- Registry status
- NA
- Development phase
- 226
- Enrollment target
NCT03065517: Completed NA study, sponsored by Evidence-Based Practice Institute, Seattle, WA.
NCT03065517 is a NA study that has completed, run by Evidence-Based Practice Institute, Seattle, WA. The registered enrollment target is 226 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03065517, a NA study, has completed, sponsored by Evidence-Based Practice Institute, Seattle, WA.
- COMPLETED
- Registry status
- NA
- Development phase
- 226 participants
- Enrollment target
Study Summary
The goal of this Phase II Small Business Innovation Research (SBIR) is to develop, evaluate, and commercialize a linked parent-youth mobile app system, VillageWhere, to support the key treatment targets of evidence-based treatments for youth with conduct disorders: clear parental expectations, parental monitoring, discipline consistency, and parental support, while simultaneously cultivating intrinsic motivation in youth toward prosocial behaviors. When used in conjunction with an evidence-based treatment for delinquent youth, VillageWhere could help reduce treatment length and cost. When provided in non-evidence-based clinical settings, VillageWhere may increase access to state-of-the-art clinical techniques to those who might not otherwise receive them. Investigators will conduct usability and acceptability tests of new features with target-end-users (youth and their parents) and key stakeholders (i.e., probation officers, clinic administrators). Once usability and acceptability is achieved, investigators will conduct a 16-week randomized controlled trial (RCT) comparing VillageWhere to an attention-control (placebo) mobile app. We expect that across four time points, VillageWhere use will result in greater improvements in parent management practices and youth autonomy support, parent-youth communication and connectedness, youth intrinsic motivation for positive behavior, and youth conduct problems than the placebo. The RCT will occur with 100 parent-youth dyads recruited from various treatment and probation settings, and represent clinically-significant conduct-problems of various clinically-significant severity levels.
Primary Outcome
Assesses parent report of youth rule-breaking, aggressive, anxious/depressed, and drug/alcohol use behaviors. Contains two subscales: rule-breaking (minimum of 0, maximum of 36) and aggressive behavior (minimum of 0, maximum of 34). Higher scores are a worse outcome.
Interventions
- DEVICE VillageWhere App
- DEVICE Attention-Control Placebo App
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2018-07-16 |
| Est. Completion | 2020-02-28 |
| Phase | NA |
What the finished NCT03065517 record still lists
NCT03065517 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which VillageWhere App is the first listed.
NCT03065517 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03065517 about?
NCT03065517 is a clinical study titled "VillageWhere: Innovative Mobile Technology for Youth With Conduct Disorder and Their Parents". The goal of this Phase II Small Business Innovation Research (SBIR) is to develop, evaluate, and commercialize a linked parent-youth mobile app system, VillageWhere, to support the key treatment targets of evidence-based treatments for youth with conduct disorders: clear parental expectations, paren...
What is the current status of trial NCT03065517?
This trial is currently completed. It is a NA study. The enrollment target is 226 participants. The study started on 2018-07-16. Estimated completion is 2020-02-28.
What interventions are being tested in trial NCT03065517?
The interventions under investigation include: VillageWhere App (DEVICE), Attention-Control Placebo App (DEVICE).
Who is sponsoring clinical trial NCT03065517?
This trial is sponsored by Evidence-Based Practice Institute, Seattle, WA, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03065517's enrollment target sits among peer trials
226 471st of 2000 higher than 1,529 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI